Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 13 12 2019
revised: 12 05 2020
accepted: 22 05 2020
pubmed: 29 5 2020
medline: 15 12 2020
entrez: 29 5 2020
Statut: ppublish

Résumé

Deregulation of cytokine signaling is frequently associated with various pathological conditions, including malignancies. In patients with myeloproliferative neoplasms (MPNs), recurrent somatic mutations in the calreticulin (CALR) gene, which encodes a molecular chaperone that resides in the endoplasmic reticulum, have been reported. Studies have defined mutant CALR as an oncogene promoting the development of MPN, and deciphered a novel molecular mechanism by which mutant CALR constitutively activates thrombopoietin receptor MPL and its downstream molecules to induce cellular transformation. The mechanism of interaction and activation of MPL by mutant CALR is unique, not only due to the latter forming a homomultimeric complex through a novel mutant-specific sequence generated by frameshift mutation, but also for its ability to interact with immature asparagine-linked glycan for eventual engagement with immature MPL in the endoplasmic reticulum. The complex formed between mutant CALR and MPL is then transported to the cell surface, where it induces constitutive activation of downstream kinase JAK2 bound to MPL. Refined structural and cell biological studies can provide an in-depth understanding of this unusual mechanism of receptor activation by a mutant molecular chaperone. Mutant CALR is also involved in modulation of the immune response, transcription, and intracellular homeostasis, which could contribute to the development of MPN. In the present article, we comprehensively review the current understanding of the underlying molecular mechanisms for mutant molecular chaperone-induced cellular transformation.

Identifiants

pubmed: 32462673
doi: 10.1111/cas.14503
pmc: PMC7419020
doi:

Substances chimiques

Calreticulin 0
Receptors, Thrombopoietin 0
Janus Kinase 2 EC 2.7.10.2

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2682-2688

Subventions

Organisme : Takeda Science Foundation
Organisme : Japan Society for the Promotion of Science
ID : #19K08848
Organisme : Japan Society for the Promotion of Science
ID : #19K17871
Organisme : Ministry of Education, Culture, Sports, Science and Technology-Supported Program for the Strategic Research Foundation at Private Universities Japan
Organisme : the Japan Leukemia Research Fund
Organisme : SENSHIN Medical Research Foundation

Informations de copyright

© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Nature. 2019 Jul;571(7765):355-360
pubmed: 31270458
J Hematol Oncol. 2016 May 13;9(1):45
pubmed: 27177927
Blood. 2016 Mar 10;127(10):1307-16
pubmed: 26817954
Nature. 1994 Feb 3;367(6462):480-3
pubmed: 8107809
Blood. 2019 Jun 20;133(25):2669-2681
pubmed: 30902807
Exp Hematol. 2016 Sep;44(9):817-825.e3
pubmed: 27185380
Cancer Sci. 2020 Aug;111(8):2682-2688
pubmed: 32462673
Nature. 1994 Feb 3;367(6462):476-80
pubmed: 8107808
Cancers (Basel). 2019 Dec 02;11(12):
pubmed: 31810292
Mol Cell Biol. 2002 Sep;22(17):6286-97
pubmed: 12167720
Cancer Discov. 2019 Sep;9(9):1192-1207
pubmed: 31266769
Oncotarget. 2018 Oct 16;9(81):35201-35202
pubmed: 30443286
Blood. 2015 Mar 5;125(10):1679-81
pubmed: 25745188
Blood Cancer J. 2019 Jan 17;9(2):8
pubmed: 30655510
Leukemia. 2019 Jan;33(1):122-131
pubmed: 29946189
Nat Rev Mol Cell Biol. 2001 Aug;2(8):627-33
pubmed: 11483996
J Biol Chem. 1999 Feb 19;274(8):4640-5
pubmed: 9988700
Blood. 2016 Mar 10;127(10):1317-24
pubmed: 26608331
Int J Hematol. 2017 Jun;105(6):743-747
pubmed: 28470469
Blood. 2018 Feb 8;131(6):649-661
pubmed: 29282219
Cytogenet Genome Res. 2006;115(1):10-5
pubmed: 16974078
Mol Cell. 2020 Feb 20;77(4):748-760.e9
pubmed: 31785928
Sci Rep. 2019 Jul 22;9(1):10558
pubmed: 31332222
JCI Insight. 2018 Nov 15;3(22):
pubmed: 30429377
Biochem J. 2009 Feb 1;417(3):651-66
pubmed: 19133842
Leukemia. 2017 May;31(5):1136-1144
pubmed: 27807369
Cancer Discov. 2016 Apr;6(4):368-81
pubmed: 26951227
Leukemia. 2018 Feb;32(2):429-437
pubmed: 28676668
N Engl J Med. 2013 Dec 19;369(25):2391-2405
pubmed: 24325359
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Blood. 2017 Feb 9;129(6):667-679
pubmed: 28028029
Blood. 2020 Jan 9;135(2):133-144
pubmed: 31697806
J Cell Biol. 2001 Jan 8;152(1):127-40
pubmed: 11149926
Blood. 2016 Mar 10;127(10):1325-35
pubmed: 26668133
J Biol Chem. 2018 Jun 22;293(25):9555-9569
pubmed: 29769311
Leukemia. 2020 Feb;34(2):499-509
pubmed: 31462733
Blood. 2018 Feb 15;131(7):782-786
pubmed: 29288169
N Engl J Med. 2013 Dec 19;369(25):2379-90
pubmed: 24325356

Auteurs

Yoko Edahiro (Y)

Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Marito Araki (M)

Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Norio Komatsu (N)

Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH